BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31547586)

  • 1. Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model.
    Zaheer J; Kim H; Lee YJ; Lim SM; Kim JS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice.
    Li HK; Morokoshi Y; Nagatsu K; Kamada T; Hasegawa S
    Cancer Sci; 2017 Aug; 108(8):1648-1656. PubMed ID: 28514062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
    Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
    Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts.
    Yamamoto Y; Yoshida M; Sato M; Sato K; Kikuchi S; Sugishita H; Kuwabara J; Matsuno Y; Kojima Y; Morimoto M; Horiuchi A; Watanabe Y
    Int J Oncol; 2011 Jan; 38(1):33-9. PubMed ID: 21109923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
    Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of
    Li HK; Morokoshi Y; Kodaira S; Kusumoto T; Minegishi K; Kanda H; Nagatsu K; Hasegawa S
    J Nucl Med; 2021 Oct; 62(10):1468-1474. PubMed ID: 33547212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
    Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
    Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.
    Bryan JN; Jia F; Mohsin H; Sivaguru G; Anderson CJ; Miller WH; Henry CJ; Lewis MR
    Cancer Biol Ther; 2011 Jun; 11(12):1001-7. PubMed ID: 21464612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
    Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.
    Heyerdahl H; Abbas N; Brevik EM; Mollatt C; Dahle J
    PLoS One; 2012; 7(8):e42345. PubMed ID: 22879947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.